[go: up one dir, main page]

WO1998005797B1 - Criblage de medicaments du cancer de la prostate - Google Patents

Criblage de medicaments du cancer de la prostate

Info

Publication number
WO1998005797B1
WO1998005797B1 PCT/US1997/013888 US9713888W WO9805797B1 WO 1998005797 B1 WO1998005797 B1 WO 1998005797B1 US 9713888 W US9713888 W US 9713888W WO 9805797 B1 WO9805797 B1 WO 9805797B1
Authority
WO
WIPO (PCT)
Prior art keywords
enhancer
cells
gene
expression
psa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/013888
Other languages
English (en)
Other versions
WO1998005797A1 (fr
WO1998005797A9 (fr
Filing date
Publication date
Priority claimed from US08/692,759 external-priority patent/US5783435A/en
Application filed filed Critical
Priority to EP97937149A priority Critical patent/EP0918884A1/fr
Priority to AU39729/97A priority patent/AU3972997A/en
Publication of WO1998005797A1 publication Critical patent/WO1998005797A1/fr
Publication of WO1998005797B1 publication Critical patent/WO1998005797B1/fr
Publication of WO1998005797A9 publication Critical patent/WO1998005797A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

On décrit le criblage de composés en vue de rechercher chez ceux-ci une activité d'inhibition de la prolifération des cellules du cancer de la prostate. On emploie une lignée cellulaire que l'on peut utiliser dans un matériel classique de détermination de l'activité de composés, dans lequel cette lignée cellulaire utilise un marqueur dont l'expression est sensible à des composés actifs sur le plan thérapeutique.
PCT/US1997/013888 1996-08-06 1997-08-06 Criblage de medicaments du cancer de la prostate Ceased WO1998005797A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97937149A EP0918884A1 (fr) 1996-08-06 1997-08-06 Criblage de medicaments du cancer de la prostate
AU39729/97A AU3972997A (en) 1996-08-06 1997-08-06 Prostate cancer drug screening

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/692,759 1996-08-06
US08/692,759 US5783435A (en) 1996-08-06 1996-08-06 Prostate cancer drug screenings

Publications (3)

Publication Number Publication Date
WO1998005797A1 WO1998005797A1 (fr) 1998-02-12
WO1998005797B1 true WO1998005797B1 (fr) 1998-05-14
WO1998005797A9 WO1998005797A9 (fr) 1998-07-09

Family

ID=24781904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013888 Ceased WO1998005797A1 (fr) 1996-08-06 1997-08-06 Criblage de medicaments du cancer de la prostate

Country Status (3)

Country Link
US (1) US5783435A (fr)
AU (1) AU3972997A (fr)
WO (1) WO1998005797A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
WO1999041413A2 (fr) * 1998-02-12 1999-08-19 Calydon, Inc. Criblage de medicament pour le traitement du cancer de la prostate
AU5801699A (en) * 1998-09-02 2000-03-21 University Of Rochester Prostate specific regulatory nucleic acid sequences
AU5723199A (en) * 1998-09-15 2000-04-03 Signalgene Inc. Marker at the androgen receptor gene for determining breast cancer susceptibility
WO2000018961A2 (fr) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate
US6872811B1 (en) 1998-09-30 2005-03-29 Millennium Pharmaceuticals, Inc. HRPCa9 and HRPCa10 nucleic acids and polypeptides
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
EP1157126A4 (fr) * 1999-02-24 2005-03-02 Gen Hospital Corp Procede de clonage de produits intermediaires de transduction de signaux
US7285414B2 (en) 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
EP1328291B1 (fr) * 2000-09-26 2008-12-24 Emory University Virus diriges sur des cellules et des tissus hypoxiques
DE10061161A1 (de) * 2000-11-30 2002-06-20 Schering Ag Neue humane Androgenrezeptor-Varianten
JP2003018987A (ja) * 2001-06-25 2003-01-21 Okazaki National Research Institutes 遺伝子導入細胞及びそれを用いた撹乱物質の検出法
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
CN1984925A (zh) * 2004-03-23 2007-06-20 肿瘤疗法科学股份有限公司 前列腺癌相关的基因和多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2169466A1 (fr) * 1993-09-01 1995-03-09 Peter Kushner Methodes pour le depistage de composes anti-oestrogeniques
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5919652A (en) * 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof

Similar Documents

Publication Publication Date Title
WO1998005797B1 (fr) Criblage de medicaments du cancer de la prostate
Yang-Yen et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction
Böttger et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Webster et al. Immediate-early transcriptional regulation and rapid mRNA turnover of a putative serine/threonine protein kinase
Baldassarre et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma
Ueki et al. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas
Link et al. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity
Brady et al. Regulation of p53 and MDM2 activity by MTBP
Eguchi et al. Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins
Rozanov et al. Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer
MX9606476A (es) Inhibicion citoplasmica de expresion de genes.
Hsu et al. Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner
Butcher et al. Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities
Sen et al. Genome-wide positioning of bivalent mononucleosomes
Kominato et al. Alternative promoter identified between a hypermethylated upstream region of repetitive elements and a CpG island in human ABO histo-blood group genes
Teo et al. The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins
Bloch et al. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth
Gu et al. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate–induced neoplastic transformation
Dong et al. 17β‐Hydroxysteroid Dehydrogenases in Human Bone Cells
AUPO128096A0 (en) Biosensors
Fu et al. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells
Lin et al. Growth inhibitory effect of the human NIT2 gene and its allelic imbalance in cancers
Kajiwara et al. SAP 155‐mediated c‐myc suppressor far‐upstream element‐binding protein‐interacting repressor splicing variants are activated in colon cancer tissues
Li et al. Cloning of the rat β-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters
Tanis et al. BLNCR is a long non-coding RNA adjacent to integrin beta-1 that is rapidly lost during epidermal progenitor cell differentiation